Federal contract award
HHSO100201700029C
IGF::OT::IGF - BASE PERIOD AWARD TO INBIOS INTERNATIONAL, INC. FOR POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $4.0M |
| Current contract value | $12.1M |
| Potential contract value / ceiling | $12.1M |
| Start date | Sep 26, 2017 |
| Current end date | Sep 30, 2027 |
| Potential end date | Sep 30, 2027 |
| Latest award activity | Aug 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 20, 2026 | P00011 | $0 | POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX |
| Sep 8, 2025 | P00010 | $63.0K | POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX |
| Aug 26, 2025 | P00009 | $0 | POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX |
| Feb 23, 2024 | P00008 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO REVISE A CLERICAL ERROR MADE IN P00007. THE FRINGE BENEFIT RATE CAP FOR CLIN 2 WAS INCORRECTLY SET AT 34% IN P00007. HOWEVER, THE NEGOTIATED FRINGE BENEFIT RATE CAP FOR CLIN 2 WAS 34.1%. THIS MODIFICAT |
| Aug 31, 2023 | P00007 | $3.9M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO CHANGE THE CONTRACTING OFFICER, CHANGE THE COR & ACOR, CHANGE THE REQUIREMENT FOR ELECTRONIC PAYMENT PROCESSING, AND EXTEND THE PERIOD OF PERFORMANCE FROM 6/30/2023 TO 09/30/2024. |
| May 31, 2023 | P00006 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO CHANGE THE CONTRACTING OFFICER, CHANGE THE COR & ACOR, CHANGE THE REQUIREMENT FOR ELECTRONIC PAYMENT PROCESSING, AND EXTEND THE PERIOD OF PERFORMANCE FROM 6/30/2023 TO 09/30/2024. |
| Jul 14, 2022 | P00005 | $0 | NO-COST SUPPLEMENTAL AGREEMENT TO EXTEND TO POP TO 06/30/2023 DUE TO CIVID -19 REPRIORITIZATIONS. NO OTHER CHANGES APPLY. |
| Nov 4, 2021 | P00004 | $0 | NO-COST SUPPLEMENTAL AGREEMENT TO INCORPORATE BY EXECUTIVE ORDER 14042 - FAR DEVIATION CLAUSE 52.223-99, ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS. NO OTHER CHANGES APPLY. |
| Jun 21, 2021 | P00003 | $0 | NO-COST EXTENSION OF PERIOD OF PERFORMANCE FROM 9/22/2021 TO 9/22/2022 TO ACCOMMODATE UNFORESEEN DELAYS AND CHANGES IN THE USG REQUIREMENTS TO FOCUS RESOURCES ON URGENT IMMEDIATE COVID-19 RESPONSE PRIORITIES. |
| Aug 24, 2020 | P00002 | $0 | NO-COST EXTENSION OF PERIOD OF PERFORMANCE FROM 9/25/2020 TO 9/22/2021, REVISED STATEMENT OF WORK AND GANTT CHART AND CHANGE CONTRACTING OFFICER FROM GEORGE J. KEANE, JR. TO JOHN K. WARNER. |
| Dec 1, 2017 | 1 | $0 | BASE PERIOD AWARD TO INBIOS INTERNATIONAL, INC. FOR POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX |
| Sep 18, 2017 | 0 | $0 | IGF::OT::IGF - BASE PERIOD AWARD TO INBIOS INTERNATIONAL, INC. FOR POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX |
Estimated positioning window
Oct 25, 2026 – Mar 30, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-30 (340 days from calculation)
- +35 points
- 6 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-08-20
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.